Aftinib Maleate / BIBW2992 DiMaleate CAS 850140-73-7 Raw Powder

CAS: 850140-73-7

MF: C28H29ClFN5O7

Specification​: 99% min BIBW2992 DiMaleate Powder

Sample:  BIBW2992 DiMaleate Powder

Brand: Henrikang

Appearance: Black Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

BIBW2992 DiMaleate Usage and Synthesis:

Afatinib bismaleate, a salt of Afatinib (BIBW2992)(B377000), is an amino-toluaniline-substituted quinazoline derivative Chemicalbook used to treat cancers and diseases of the respiratory tract, lungs, gastrointestinal tract, bile duct and gallbladder. An aniline quinazoline that irreversibly inhibits EGFR and HER2 kinase activity.

BIBW2992 DiMaleate is a drug used in the treatment of non-small cell lung cancer (NSCLC) and other types of cancer. It  is also known as afatinib dimaleate and is a tyrosine kinase inhibitor that works by blocking the activity of certain  proteins that are involved in the growth and spread of cancer cells.

BIBW2992 DiMaleate is administered orally and is usually taken once a day. It is important to follow the dosage  instructions provided by the healthcare provider.

The drug may cause side effects such as diarrhea, skin rash, nausea, vomiting,  and fatigue. These side effects can be managed with medication and other supportive measures.

BIBW2992 DiMaleate is not recommended for use in pregnant women as it may harm the developing fetus. It is important to  inform the healthcare provider if you are pregnant or planning to become pregnant before starting the treatment.

Overall,  BIBW2992 DiMaleate is an effective treatment option for NSCLC and other types of cancer. It is important to discuss the  benefits and risks of the drug with the healthcare provider before starting the treatment.

Pharmacokinetics of BIBW2992 DiMaleate:

Afatinib bis-maleate is an organic synthesis intermediate and Pharmaceutical intermediate that can be used in laboratory research and development processes and in chemical and pharmaceutical synthesis processes. Afatinib is a new generation oral small molecule tyrosine kinase inhibitor (TKI) and an irreversible ErbB family blocker.

Clinical Application of BIBW2992 DiMaleate:

1, Locally advanced or metastatic non-small cell lung cancer (NSCLC) with an epidermal growth factor receptor (EGFR) sensitive mutation, not previously treated with an EGFR tyrosine kinase inhibitor (TKI).

2. Locally advanced or metastatic squamous histologic type non-small cell lung cancer (NSCLC) with disease progression during or after platinum-containing chemotherapy.